All Posts Tagged With: "DNDN"
(DNDN) Dendreon’s Provenge Showing Bleak Outlook
Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate...
(DNDN) Dendreon Loss Narrows
Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus...
(DNDN) Dendreon Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results.
Dendreon Corporation reported weaker-than-expected...
(AAPL) Company News for July 5, 2011 – Corporate Summary
• Eastman Kodak Co. (NYSE:EK) received a mixed ruling from the U.S. International Trade Commission on its patent infringement suit against Research In Motion Limited (NASDAQ:
5Jul2011 | vitalstocks | 0 comments | Continued(DNDN) Medicare to Cover Dendreon’s Provenge
Dendreon Corporation (DNDN) has of late been announcing significant milestones, related to its potential blockbuster cancer vaccine Provenge. Most recently, the company announced that the Centers for Medicare...
(DNDN) Dendreon Gets FDA Clearance on Second Facility
Dendreon Corporation (DNDN) recently received clearance from the U.S. Food and Drug Administration (FDA) to expand manufacturing facility for its cancer vaccine Provenge, in the U.S. The company’s Los Angeles...
(AFFX) Company News for June 03, 2011 – Corporate Summary
• Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038...
(JNJ) Johnson and Johnson Earns FDA Approval for Cancer Drug
Johnson and Johnson (JNJ) recently announced US Food and Drug Administration (FDA) approval for its prostate cancer therapy, Zytiga (abiraterone acetate). Zytiga, an oral, once-daily medication, gained approval...
(DNDN) Dendreon Corporation Cuts Loss on Provenge Sales
Dendreon Corporation’s (DNDN) first quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 69 cents per share was in line with the Zacks Consensus Estimate....
(DNDN) Dendreon Learns Medicare May Pay for Provenge Prostate Cancer Vaccine
Dendreon Corporation (DNDN) received a huge boost today when the Centers for Medicare and Medicaid Services (CMS) proposed to pay for its lead prostate cancer vaccine Provenge.
Provenge was approved...
(DNDN) Dendreon Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $39.00 following the announcement of fourth quarter and full year 2010 financial results.
Dendreon’s...
(ACXM) Company News for April 01, 2011 – Corporate Summary
• Hershey (NYSE:HSY) said it raised wholesale prices by 9.7% due to fuel, raw materials and transportation costs
• According to a Bloomberg report, regulators reported that Dendreon Corp.’s (NASDAQ:
1Apr2011 | vitalstocks | 0 comments | Continued(BAC) Company News for December 1, 2010 – Corporate Summary
• State Street (NYSE:STT) said it will lay off 1,400 jobs, or 5% of its workforce
• RLI (NYSE:RLI) said it will pay a $7.00 per share special dividend
• Bank of America (NYSE:BAC) initiated coverage of Dendreon (NASDAQ:DNDN) with a “buy”...
(DNDN) These Biotech Stocks Are Just What the Doctor Ordered
by Louise Harris, Investment U Research
Thursday, January 28, 2010
They say that one in every nine women will get breast cancer.
It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some...
(DNDN) Dendreon Corporation Prices Stock Offer
Dendreon Corporation (DNDN) announced recently that it has priced its common stock at $24.75 per share in its public offering to sell 15 million shares of common stock. The offer is underwritten by JP Morgan...
(DNDN) Dendreon Corporation Raising Money
Dendreon Corporation (DNDN) announced recently that it will sell 15 million shares of common stock in a public offering underwritten by JP Morgan Securities, a division of JP Morgan Chase & Co...
(DNDN) Dendreon’s Provenge Gets Action Date Assigned
Recently, Dendreon Corp. (DNDN) announced that the U.S. Food and Drug Administration (FDA) has accepted the amended Biologics...
(DNDN) Dendreon’s Reached Orbit – Now Who’s Next?
by Robert Williams, Publisher
When the...
(DNDN) Dendreon Corporation: Put These Two Promising Biotech Stock on Your Watch List
by Louis Basenese, Small Cap and Special Situations...
($DNDN) Dendreon to Seek FDA Approval for Prostate Cancer Vaccine, Provenge
Recently, Dendreon Corp. (DNDN) announced that it intends to file an amendment to its existing Biologic License Application (BLA) for its prostate cancer vaccine Provenge in Nov. 2009. We believe that the US Food and Drug Administration (FDA) will approve...